In early July, the FDA held a major hearing near Washington, DC, addressing the regulatory status of a group of compounded peptides — and Jessica was there. In this episode, Dr. Kylie Burton and Jessica Briecke break down what actually happened at the hearing (as opposed to the wave of secondhand opinions that circulated online afterward).
And shocker, we were the ONLY company who showed up! And we showed up in full force.
So what happened and what did the FDA hearing mean to the peptide industry? Jessica explains as she was there.
Jessica explains the regulatory shift at the center of the issue: twelve peptides were reclassified from a "Category 1" to "Category 2" status for compounding pharmacies, a change that significantly limits legal access. The hosts argue that restricting supply doesn't reduce demand — it pushes people toward unregulated "gray market" and research-chemical sites, where testing has reportedly turned up contaminants like arsenic and lead, and in some cases, no actual peptide at all in the product. They also talk about the risks of at-home reconstitution using instructions found on social media or generated by AI, done without pharmacist training or a sterile environment.
The episode closes with a recap of the advocacy work itself — testimony at the hearing, meetings with congressional offices, and a broader case for regulation (not elimination) of compounded peptides — plus an invitation to a live business information session for anyone interested in partnering with the hosts' telemedicine company.
What You'll Learn
- What changed: twelve peptides were moved from Category 1 to Category 2 status for compounding pharmacies, restricting legal access
- Why the hosts argue that restricting legal, regulated supply pushes demand toward the gray/black market instead of eliminating it
- What third-party testing has reportedly found in unregulated "research-grade" peptide powders — including contaminants and products containing no actual peptide
- The risks of at-home reconstitution using unofficial instructions, without pharmacist training or a sterile environment
- The distinction the hosts draw between eliminating access and pushing for regulation, medical oversight, and domestic manufacturing standards
- A firsthand account of the hearing itself, including testimony from the company's CEO and returning guest Dr. Joelle Osias
Have you been thinking about joining us as a affiliate? Come join us on September 22nd for a LIVE zoom session to learn more and get started. Register and get the details here: drkylieburton.com/register
You can also always connect withConnect With Us
- Jessica Brickie: Instagram @jessb.talkshealth | b2bwithjess.com
- Dr. Kylie Burton: drkylieburton.com | Amplify Program
Where do you start with peptide therapy? What do you add next? If you're a go-getter, check out Dr. Kylie's new program AMPLIFY. You'll find it on the homepage of her website: drkylieburton.com
Ready to explore peptide therapy for yourself? Join through Jessica's platform at B2BwithJess.com/peptides or through Dr. Kylie's platform at drkylieburton.com/shop.
Want to offer peptide therapy in your business? Whether you're adding it to your existing practice or building something new, learn how to get started—and how we'll mentor you along the way—at drkylieburton.com/peptidesaffiliate. You can also get started through Jessica's platform at B2BwithJess.com.
Legal Disclaimer: This podcast is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new health protocol. Dr. Kylie Burton and Jessica Briecke are affiliates and may receive compensation for referrals. Individual results may vary.
You have the science. You have the tools. Now it's time to take the next step.
This is PepTalk: Peptides Unpacked—science made simple, re...